This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Why I Sold Baxter And CareFusion

Stock quotes in this article: BAX, CFN, JAZZ

By Robert Freedland

The Covestor Healthcare portfolio that I manage did not escape the effects of the August sell-off which resulted in a 3.5% loss for the S&P 500 Index (SPX), the biggest dip since a 6.3% drop in May, 2012.

There were a couple of changes that were made in this portfolio although most of the stocks remained unchanged.

I sold my position in Baxter (BAX) with a modest gain. Overall I was unimpressed with the 2nd quarter results as reviewed by Zacks, with earnings climbing 4% and revenue growth growing 3%. The stock price movement was somewhat anemic and with the overall market less than stellar, I chose to part ways with this dividend-paying healthcare stock. Here is the ‘point & figure’ chart on Baxter from StockCharts.com.

In addition, I sold my position in CareFusion (CFN), also in the midst of a weak stock market environment. The stock reported earnings that missed expectations as Zacks explains and revenue actually decreased. Here is the ‘point and figure’ chart on CFN from StockCharts.

The chart actually looks relatively strong but I prefer to find stocks that at least meet earnings expectations at have growing revenue.

During August, I purchased shares of Jazz Pharmaceuticals (JAZZ). This pharmaceutical firm makes a variety of products for various medical needs as this Yahoo ‘Profile’ describes.

On August 6, 2013, JAZZ reported 2nd Quarter 2013 results. aEarnings climbed to $88.3 million or $1.43/diluted share from $66.2 million or $1.09/diluted share the prior year. Total revenues for the quarter came in at $208.3 million up from $124.2 million the prior year.

They also moved ahead and raised guidance for the full year 2013. aIf we look at the ‘point & figure’ chart from StockCharts.com we can see the strong price appreciation in this stock:

As with all of my Covestor portfolios, the Covestor Healthcare Model gives me the opportunity to utilize my own background in Healthcare to help me understand diseases and their treatments and my own passion in investing to identify potential winners in the market.

Having been an investor for many years, I know there is no guarantee of future performance based on past performance but I am optimistic that the Healthcare field will be a dynamic place to invest as new drugs, new therapies, and new means of delivering that care will be an ongoing challenge for all of us.

The investments discussed are held in client accounts as of August 31, 2013. These investments may or may not be currently held in client accounts. The reader should not assume that any investments identified were or will be profitable or that any investment recommendations or investment decisions we make in the future will be profitable.

Robert Freedland

Robert Freedland

Robert has over 40 years of investment experience and is a full-time optical surgeon. He uses his expertise in the

null

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs